세계 기침 시럽 시장 규모는 2024년 61억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 85억 달러에 달해 2025년부터 2033년까지 3.65%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다. 상기도 감염(UTI) 및 기타 호흡기질환의 증가와 함께 일반 상점과 약국에서 기침 시럽을 쉽게 구할 수 있게 된 것이 시장 성장의 주요 원동력이 되고 있습니다.
의료 상황 확대
감기, 독감, 기관지염, 백일해, 천식, 만성폐쇄성폐질환(COPD), 알레르기의 유병률 증가는 기침 시럽의 수요를 촉진하고 있습니다. 예를 들어, 이코노믹 타임즈가 2023년 발표한 기사에 따르면, 전 세계적으로 약 3억 3,900만 명이 천식을 앓고 있다고 합니다. 또한, 담배 소비의 증가와 건강에 해로운 생활 습관으로 인한 기침 사례의 증가도 시장 성장을 촉진하고 있습니다. 이 외에도 세계보건기구(WHO)에 따르면 매년 800만 명 이상이 담배 소비로 인해 조기에 사망합니다. 이 중 700만 명이 직접 흡연자이고, 170만 명이 간접흡연자입니다. 따라서 정부 및 비정부기구는 국민들의 인식을 높이기 위해 많은 프로그램과 캠페인을 전개하고 있습니다. 예를 들어, 2023년 7월 호주 폐 재단은 성인과 소아과에서 만성 기침에 대한 인식을 높이고 진단을 돕기 위한 캠페인을 시작했습니다. 여기에 더해 노령 인구의 증가는 기침 시럽 시장 전망에 더욱 기여하고 있습니다. 예를 들어, WHO에 따르면 2020년에는 60세 이상 노인이 10억 명, 2050년에는 21억 명에 달할 것으로 예상하고 있습니다.
정부기관의 규제 환경
각국의 규제 당국은 기침 시럽의 주요 기업들이 높은 의료 기준을 준수하도록 엄격한 규정을 시행하고 있습니다. 이에 따라 제네릭 의약품 개발에 대한 의료진의 인식이 높아지면서 최근 기침 시럽 시장 개척에 박차를 가하고 있습니다. 예를 들어, 인도 의약품 총국(DCGI)은 모든 주와 연방 직할령에 보낸 서한을 통해 인도에서 생산되는 기침 시럽이 세계 표준 품질인지 확인하고, 이를 위해 상세한 검증을 실시할 것을 요청했습니다. 이에 따라 프로필렌 글리콜(PG) 제조업체, 기침시럽 제조업체, 수입업체에 기침시럽 제조에 사용되거나 공급되는 원료가 세계 표준 프로토콜에 부합하는지 확인하기 위한 공동 검증을 요청했습니다. 또한 세계보건기구(WHO)는 또 다른 기침약 시럽에 오염물질이 존재한다고 경고했습니다. WHO는 2022년 7월에 오염 가능성에 대한 보고를 받고 특정 배치의 샘플을 검사했습니다. 이 기침 시럽은 Fourrts Laboratories사가 인도 Dabilife Pharma사를 대신해 제조한 제품입니다. 이러한 엄격한 규제와 점검을 통해 제품의 품질이 향상되고 향후 몇 년 동안 기침 시럽 시장의 수익을 촉진할 것으로 예상됩니다.
전략적 제휴
유명 대기업들이 M&A에 뛰어들었고, 보통 면역력 강화 효과가 있는 천연 성분이나 허브를 함유한 참신한 제품 개발을 위해 끊임없이 노력하고 있습니다. 이것이 시장을 발전시키고 있습니다. 예를 들어, 2023년 GSK plc는 캐나다의 생명공학 기업 중 하나인 Bellus Health를 20억 달러에 인수하는 계약을 체결했습니다. 이번 인수는 GSK의 임상 파이프라인 포트폴리오와 세계 시장에서의 입지를 강화하기 위해 이루어졌습니다. 이 포트폴리오에는 시럽 및 기타 제제도 포함되어 있으며, 기침 시럽의 시장 점유율이 증가했습니다. 마찬가지로, 2023년 12월 미국 FDA는 성인 난치성 만성 기침(RCC) 치료제 중 하나인 게파픽산트에 대한 머크의 신약허가신청(NDA)에 대해 CRL(Complete Response Letter)을 발행했습니다. 주요 기업들은 소비자층을 확대하기 위해 천연 성분을 함유한 기침 시럽을 추가로 출시하고 있으며, 이것이 기침 시럽 시장의 최근 동향입니다. 예를 들어, Vitae Health Innovation사는 엘더베리, 백리향, 알테아, 청미래덩굴, 바다 갈매나무 추출물을 배합한 천연 시럽 VitatusS를 출시하였습니다. 또한, Sun Pharmaceutical Industries Ltd.는 기침약 'Chericof 12'를 출시했다고 발표했습니다. 회사 측에 따르면, 이 제품은 인도 최초의 처방전 기침 시럽으로 최대 12시간 동안 기침을 완화하는 효과가 있습니다.
The global cough syrup market size reached USD 6.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.65% during 2025-2033. The increasing occurrence of upper respiratory tract infections (URTIs) and other respiratory disorders, along with the easy availability of cough syrups in general stores and pharmacies, is primarily driving the market growth.
Growing Medical Conditions
The rising prevalence of cold, flu, bronchitis, pertussis, asthma, chronic pulmonary obstructive disease (COPD), and allergies is driving the need for cough syrups. For example, according to an article published by the Economic Times in 2023, around 339 million individuals are affected by asthma globally. Furthermore, the elevating cough cases, owing to the increasing tobacco consumption and unhealthy lifestyles, are also stimulating the market growth. Besides this, as per the World Health Organization (WHO), every year, more than 8 million people die prematurely from tobacco consumption. Among these, 7 million are direct smokers, and 1.7 million are second-hand smokers. Consequently, government and non-government organizations are launching numerous programs and campaigns to generate awareness among the population. For example, in July 2023, the Lung Foundation in Australia launched a chronic cough awareness campaign to raise awareness and support diagnosis in adults and pediatrics. In addition to this, the expanding geriatric population is further contributing to the cough syrup market outlook. For instance, according to the WHO, individuals aged 60 and above were 1 billion in 2020 and are expected to reach 2.1 billion by 2050.
Regulatory Environment by Government Bodies
Regulatory authorities across countries are implementing stringent rules to ensure leading companies of cough syrups comply with high medical standards. In line with this, they are generating awareness among healthcare professionals to develop generic drugs, thereby catalyzing the cough syrup market recent opportunities. For instance, in a letter written to all states and union territories, the Drugs Controller General of India (DCGI) asked to ensure that cough syrups produced in India are of global standard quality for which a detailed verification should be undertaken. In line with this, he asked for a joint verification drive on propylene glycol (PG) manufacturers, cough syrup manufacturers, and importers to ensure that the raw material utilized or supplied for the manufacturing of cough syrups is as per the global protocol. Additionally, the World Health Organization (WHO) has flagged another cough syrup for the presence of contaminants. The WHO tested a sample from a specific batch of the syrup after it received a report in July 2022 regarding possible contamination. Fourrts Laboratories produced the cough syrup on behalf of another company in India called Dabilife Pharma. These stringent regulations and checks will improve the quality of products, which is expected to propel the cough syrup market revenue in the coming years.
Strategic Alliances
Prominent key players are entering into mergers and acquisitions and are constantly working towards novel product developments that are usually formulated with natural ingredients and herbs with immunity-boosting effects. This, in turn, is driving the market forward. For example, in 2023, GSK plc. signed an acquisition deal with one of the Biotech firms in Canada, Bellus Health, for US$ 2 Billion. This deal was done to strengthen GSK's clinical pipeline portfolio and market position across the globe. The portfolio also included syrups and other formulations, thereby elevating the cough syrup market share. Similarly, in December 2023, the U.S. FDA issued a complete response letter (CRL) about Merck's new drug application (NDA) for gefapixant, one of the drugs to treat refractory chronic cough (RCC) in adults. Key players are further introducing cough syrups with natural ingredients to expand their consumer base, which is cough syrup market recent developments. For instance, Vitae Health Innovation launched VITATUSS, a natural syrup formulated with elderberry, thyme, althaea, mallow, and sea buckthorn extract. In line with this, Sun Pharmaceutical Industries Ltd. announced the introduction of a formulation in cough management called Chericof 12. The company said this was the first prescription cough syrup across India that offer relief for up to 12 hours.
Currently, cough suppressants/antitussives account for the majority of the global market share
Symptoms related to cold and cough are usually managed by utilizing over the counter (OTC) medicines. Cough suppressants, or antitussive drugs, are medicines that are adopted to control and relieve a cough. While many antitussives are widely accessible OTC, a few antitussives are only available with a prescription. Antitussives are used in various types of formulations, such as capsules, liquids, tablets, and syrups. For example, Dextromethorphan, one of the most widely utilized cough suppressants in the U.S., was compared with codeine, the traditional antitussive in Europe, in a double-blind, crossover trial using both subjective and objective assessment of efficacy in sixteen patients with chronic cough. Dextromethorphan lowered cough intensity more than codeine and was considered the better antitussive by most patients. This, in turn, represents key factors propelling the cough syrup market growth in the segmentation.
Adult currently holds the largest market share
Adults commonly suffer from chronic and acute cough, owing to unhealthy lifestyles and high exposure to tobacco. For example, as per the study published by the European Respiratory Society in 2020, approximately 10% of the adult population suffers from chronic cough, on account of the impaired quality of life. Consequently, the expanding adult population is escalating the cough syrup market demand, thereby stimulating the adoption of cough remedies.
Currently, retail pharmacy exhibits a clear dominance in the market
As per the cough syrup market overview, the easy product availability via distribution channels, such as retail pharmacy, owing to its accessibility and convenience, is bolstering the segmentation growth. For example, according to the Federal Union of German Associations of Pharmacists (ABDA, around 18,068 community pharmacies across Germany cater to medical needs in 2023. In addition to this, the rising number of generic and branded remedy products in retail pharmacy chains, including Walmart Stores Inc. and Walgreens, is further acting as another significant growth-inducing factor. Moreover, the increasing tie-ups of hospitals with these chains are strengthening the cough syrup market recent price.
According to the cough syrup market statistics, Asia Pacific exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.
The regional market is primarily driven by the numerous partnerships among pharmaceutical companies and government organizations, generally to develop novel generic drugs and generate awareness among individuals and healthcare professionals. Moreover, key players are emphasizing on innovative packaging solutions, which is contributing to the growth of the market. Apart from this, the inflating expenditure capacities of individuals across the region and the elevating focus on preventive healthcare are further validating the cough syrup market forecast. According to a report by the FMCG Gurus, more than 55% of people in the Asia Pacific region have been more conscious about boosting their immunity since the sudden outbreak of the COVID-19 pandemic.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include: